Bivictrix Therapeutics LTD

bivictrix is a uk-based oncology-focused biotech company founded to exploit the bi-cygni technology, enabling the discovery and development of a new class of bispecific bio-therapeutics with improved potency and enhanced therapeutic index. monospecific bio-therapeutics targeting a single antigen have shown considerable therapeutic benefit in a number of cancer indications. however the application of these drugs is currently limited by the widespread expression of these targets on healthy tissues, leading to often debilitating and sometimes fatal, on-target off-tissue toxicities. this lack of true cancer specificity has resulted in many targeted bio-therapeutics being removed from clinical trials and is one of the major factors limiting the development of this otherwise promising therapeutic class. bivictrix's bi-cygni therapeutics are engineered to selectively target a unique cancer-restricted antigen co-expression pattern, absent from healthy cells. the bi-cygni technology links to